We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
featured
Published in Cardiology

Journal Scan / Review · December 17, 2020

Efficacy of Tafamidis in Patients With Hereditary and Wild-Type Transthyretin Amyloid Cardiomyopathy

JACC: Heart Failure

 

Additional Info

Disclosure statements are available on the authors' profiles:

JACC: Heart Failure
Efficacy of Tafamidis in Patients With Hereditary and Wild-Type Transthyretin Amyloid Cardiomyopathy: Further Analyses From ATTR-ACT
JACC Heart Fail 2020 Dec 02;[EPub Ahead of Print], C Rapezzi, P Elliott, T Damy, J Nativi-Nicolau, JL Berk, EJ Velazquez, K Boman, B Gundapaneni, TA Patterson, JH Schwartz, MB Sultan, MS Maurer

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading